Fmr LLC Connect Biopharma Holdings LTD Transaction History

Fmr LLC

Previous 0 NaN%

Previous $0 NaN%

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.28 - $2.2 $0 - $0	0 New	0 $0
Q1 2024 May 13, 2024	SELL	$1.01 - $1.74 $23 - $40	-23 Closed	0 $0
Q4 2023 Feb 13, 2024	SELL	$0.7 - $2.06 $0 - $2	-1 Reduced 4.17%	23 $0
Q2 2023 Aug 11, 2023	SELL	$1.01 - $1.25 $9 - $11	-9 Reduced 27.27%	24 $0
Q1 2023 May 11, 2023	SELL	$0.82 - $1.32 $41 - $66	-50 Reduced 60.24%	33 $0
Q4 2022 Feb 13, 2023	SELL	$0.64 - $1.31 $2 - $5	-4 Reduced 4.6%	83 $0
Q3 2022 Nov 10, 2022	SELL	$0.8 - $1.65 $77 - $160	-97 Reduced 52.72%	87 $0
Q2 2022 Aug 12, 2022	SELL	$0.56 - $3.25 $1.28 Million - $7.42 Million	-2,283,085 Reduced 99.99%	184 $0
Q1 2022 May 13, 2022	SELL	$2.46 - $5.92 $2.79 Million - $6.72 Million	-1,134,295 Reduced 33.19%	2,283,269 $6.89 Million
Q4 2021 Feb 14, 2022	SELL	$4.26 - $23.33 $5.97 Million - $32.7 Million	-1,400,625 Reduced 29.07%	3,417,564 $17.6 Million
Q3 2021 Nov 15, 2021	BUY	$18.12 - $28.5 $16.2 Million - $25.4 Million	892,353 Added 22.73%	4,818,189 $117 Million
Q2 2021 Aug 13, 2021	BUY	$14.16 - $19.53 $55.6 Million - $76.7 Million	3,925,836 New	3,925,836 $76.7 Million

2.98M

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $71M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

Stay updated on Fmr LLC with notifications on news.